VRCA vs. ALDX, VOR, CRVS, SGMT, DBVT, ANNX, AVTE, ALLO, TVRD, and ZYBT
Should you be buying Verrica Pharmaceuticals stock or one of its competitors? The main competitors of Verrica Pharmaceuticals include Aldeyra Therapeutics (ALDX), Vor Biopharma (VOR), Corvus Pharmaceuticals (CRVS), Sagimet Biosciences (SGMT), DBV Technologies (DBVT), Annexon (ANNX), Aerovate Therapeutics (AVTE), Allogene Therapeutics (ALLO), Tvardi Therapeutics (TVRD), and Zhengye Biotechnology (ZYBT). These companies are all part of the "pharmaceutical products" industry.
Verrica Pharmaceuticals vs. Its Competitors
Verrica Pharmaceuticals (NASDAQ:VRCA) and Aldeyra Therapeutics (NASDAQ:ALDX) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their media sentiment, dividends, analyst recommendations, valuation, institutional ownership, earnings, profitability and risk.
Verrica Pharmaceuticals' return on equity of 0.00% beat Aldeyra Therapeutics' return on equity.
Verrica Pharmaceuticals has a beta of 1.76, suggesting that its share price is 76% more volatile than the S&P 500. Comparatively, Aldeyra Therapeutics has a beta of 0.9, suggesting that its share price is 10% less volatile than the S&P 500.
In the previous week, Aldeyra Therapeutics had 1 more articles in the media than Verrica Pharmaceuticals. MarketBeat recorded 2 mentions for Aldeyra Therapeutics and 1 mentions for Verrica Pharmaceuticals. Aldeyra Therapeutics' average media sentiment score of 0.71 beat Verrica Pharmaceuticals' score of 0.00 indicating that Aldeyra Therapeutics is being referred to more favorably in the news media.
Aldeyra Therapeutics has lower revenue, but higher earnings than Verrica Pharmaceuticals. Aldeyra Therapeutics is trading at a lower price-to-earnings ratio than Verrica Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Verrica Pharmaceuticals currently has a consensus target price of $8.00, indicating a potential upside of 1,008.03%. Aldeyra Therapeutics has a consensus target price of $9.50, indicating a potential upside of 77.24%. Given Verrica Pharmaceuticals' higher possible upside, equities analysts plainly believe Verrica Pharmaceuticals is more favorable than Aldeyra Therapeutics.
42.5% of Verrica Pharmaceuticals shares are held by institutional investors. Comparatively, 59.7% of Aldeyra Therapeutics shares are held by institutional investors. 54.0% of Verrica Pharmaceuticals shares are held by insiders. Comparatively, 8.5% of Aldeyra Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.
Summary
Aldeyra Therapeutics beats Verrica Pharmaceuticals on 8 of the 14 factors compared between the two stocks.
Get Verrica Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for VRCA and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding VRCA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Verrica Pharmaceuticals Competitors List
Related Companies and Tools
This page (NASDAQ:VRCA) was last updated on 7/22/2025 by MarketBeat.com Staff
